Fang-Fang Kong1,2,3,4, Guang-Sen Pan1,2,3,4, Rui-Ping Zhai1,2,3,4, Cheng-Run Du1,2,3,4, Xia-Yun He1,2,3,4, Chun-Ying Shen1,2,3,4, Xue-Guan Lu1,2,3,4, Tuan-Qi Sun2,5, Yu Wang2,5, Qing-Hai Ji2,5, Chao-Su Hu6,7,8,9, Hong-Mei Ying10,11,12,13. 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China. 3. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China, 20032. 4. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China, 20032. 5. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. 6. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. hucsu62@163.com. 7. Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China. hucsu62@163.com. 8. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China, 20032. hucsu62@163.com. 9. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China, 20032. hucsu62@163.com. 10. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China. yinghongmei2013@163.com. 11. Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China. yinghongmei2013@163.com. 12. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China, 20032. yinghongmei2013@163.com. 13. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China, 20032. yinghongmei2013@163.com.
Abstract
BACKGROUND: To review our long-term clinical experience, analyze the failure patterns, and give suggestions for target volume delineation of carcinoma showing thymus-like differentiation (CASTLE) treated with intensity-modulated radiotherapy (IMRT). METHODS: From April 2008 to May 2019, 30 patients with CASTLE treated by postoperative or radical IMRT in our center were retrospectively reviewed. A total dose of 56-60 Gy in 28-30 fractions was prescribed to patients without residual disease and 66 Gy in 33 fractions for patients with residual or unresectable disease. Survival rates were calculated using the Kaplan-Meier method. Treatment-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0. RESULTS: Among the 30 patients, 12 (40%) received partial resection or biopsy. Lateral lymph node metastasis was observed in 7 (23.3%) patients. During follow-up, regional lymph node recurrence occurred in 2 patients and distant metastasis in 5 patients. With a median follow-up time of 63.5 months, the 5-year local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS), overall survival (OS) and progression-free survival (PFS) rates were 100, 88.9, 78.9, 93.1 and 78.9%, respectively. For patients with no lateral neck node metastasis, prophylactic radiotherapy for lateral neck nodal regions failed to improve RRFS (p = 0.381) and OS (p = 0.153). CONCLUSION: Distant metastasis was the major failure pattern for CASTLE after surgery and IMRT. For patients with no lateral neck node metastasis, the omission of irradiation for lateral neck nodal regions seems to be safe and feasible.
BACKGROUND: To review our long-term clinical experience, analyze the failure patterns, and give suggestions for target volume delineation of carcinoma showing thymus-like differentiation (CASTLE) treated with intensity-modulated radiotherapy (IMRT). METHODS: From April 2008 to May 2019, 30 patients with CASTLE treated by postoperative or radical IMRT in our center were retrospectively reviewed. A total dose of 56-60 Gy in 28-30 fractions was prescribed to patients without residual disease and 66 Gy in 33 fractions for patients with residual or unresectable disease. Survival rates were calculated using the Kaplan-Meier method. Treatment-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0. RESULTS: Among the 30 patients, 12 (40%) received partial resection or biopsy. Lateral lymph node metastasis was observed in 7 (23.3%) patients. During follow-up, regional lymph node recurrence occurred in 2 patients and distant metastasis in 5 patients. With a median follow-up time of 63.5 months, the 5-year local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS), overall survival (OS) and progression-free survival (PFS) rates were 100, 88.9, 78.9, 93.1 and 78.9%, respectively. For patients with no lateral neck node metastasis, prophylactic radiotherapy for lateral neck nodal regions failed to improve RRFS (p = 0.381) and OS (p = 0.153). CONCLUSION: Distant metastasis was the major failure pattern for CASTLE after surgery and IMRT. For patients with no lateral neck node metastasis, the omission of irradiation for lateral neck nodal regions seems to be safe and feasible.